Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Given Average Recommendation of “Hold” by Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have earned a consensus rating of “Hold” from the five analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have given a buy recommendation to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.10.

A number of equities analysts have recently commented on RXRX shares. Wall Street Zen lowered shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Morgan Stanley increased their price target on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Bank of America decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a report on Thursday, April 30th.

Insider Transactions at Recursion Pharmaceuticals

In other news, CFO Ben R. Taylor sold 7,956 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the transaction, the chief financial officer owned 1,180,318 shares of the company’s stock, valued at $4,001,278.02. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Blake Borgeson sold 30,000 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $3.68, for a total transaction of $110,400.00. Following the completion of the transaction, the director directly owned 6,169,863 shares in the company, valued at $22,705,095.84. The trade was a 0.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 125,930 shares of company stock valued at $435,942 in the last quarter. Insiders own 6.65% of the company’s stock.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in RXRX. Brighton Jones LLC grew its holdings in shares of Recursion Pharmaceuticals by 49.4% during the 4th quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after purchasing an additional 6,699 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Recursion Pharmaceuticals by 627.6% during the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after purchasing an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth bought a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at $77,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock opened at $3.15 on Wednesday. The firm’s 50 day simple moving average is $3.32 and its 200 day simple moving average is $3.78. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $1.67 billion, a PE ratio of -2.62 and a beta of 1.04. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.08. The firm had revenue of $6.47 million for the quarter, compared to analyst estimates of $15.78 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The business’s revenue for the quarter was down 56.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.50) EPS. As a group, analysts expect that Recursion Pharmaceuticals will post -0.99 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.